Cyclacel Pharmaceuticals (NASDAQ:CYCC) Announces Earnings Results, Beats Expectations By $0.36 EPS

Cyclacel Pharmaceuticals (NASDAQ:CYCC) released its quarterly earnings data on Tuesday. The biotechnology company reported ($0.18) EPS for the quarter, topping the consensus estimate of ($0.54) by $0.36, Zacks reports. Cyclacel Pharmaceuticals had a negative return on equity of 1,901.11% and a negative net margin of 18,150.00%. The business had revenue of $0.01 million for the quarter, compared to analyst estimates of $0.01 million.

Cyclacel Pharmaceuticals Stock Performance

Shares of NASDAQ CYCC traded up $0.01 during mid-day trading on Wednesday, reaching $0.42. 12,071,661 shares of the company’s stock were exchanged, compared to its average volume of 709,693. The company’s 50-day moving average is $0.89 and its 200-day moving average is $1.45. Cyclacel Pharmaceuticals has a 52-week low of $0.37 and a 52-week high of $7.84. The firm has a market capitalization of $892,465.00, a price-to-earnings ratio of -0.05 and a beta of 0.56.

Wall Street Analyst Weigh In

CYCC has been the topic of several recent research reports. StockNews.com initiated coverage on Cyclacel Pharmaceuticals in a research report on Thursday, November 7th. They issued a “sell” rating on the stock. Roth Capital lowered Cyclacel Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, October 23rd.

About Cyclacel Pharmaceuticals

Cyclacel Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases in the United States, the United Kingdom, and internationally. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors and hematological malignancies, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors and hematological malignancies.